Sarcoidosis is a rare inflammatory condition that develops when groups of cells in your immune system form patches of swollen ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

More than 10,000 homes and other structures were consumed by flames, along with thousands of cars and other vehicles.

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call was “relatively uneventful” besides an announcement for ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Roivant Sciences Ltd (ROIV) showcases strong financials and strategic advancements while navigating ongoing litigation and competitive pressures.

Sean Hull, PNC Bank’s market leader in Baltimore, helps clients use banking services to achieve their financial goals.

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

The show easily stands next to the best binge-able shows on Netflix right now.

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...